Radioiodinated MIBG in paraganglioma and pheochromocytoma: previous results and early experiences using no-carrier-added MIBG

Nuclear Medicine and Biology

Volumn 35, Issue SUPPL.1, 2008, Pages

  James, Olga ^a   Coleman, R Edward ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

MIBG; No carrier added; Paraganglioma; Pheochromocytoma

Indexed keywords

(3 IODOBENZYL)GUANIDINE; (3 IODOBENZYL)GUANIDINE I 123; (3 IODOBENZYL)GUANIDINE I 131; CYCLOPHOSPHAMIDE; DACARBAZINE; DOPA; FLUOROURACIL; GALLIUM 68; PENTETREOTIDE; PENTETREOTIDE IN 111; SOMATOSTATIN; STREPTOZOCIN; SUCCINATE DEHYDROGENASE; SUCCINATE DEHYDROGENASE B; UNCLASSIFIED DRUG; VINCRISTINE;

ANOREXIA; BIOCHEMISTRY; BLOOD TOXICITY; CANCER INVASION; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; GENE MUTATION; HUMAN; HYPOTHYROIDISM; ISOTOPE LABELING; LEUKOPENIA; MALIGNANT NEOPLASTIC DISEASE; METASTASIS; MORTALITY; NAUSEA; NEUROENDOCRINE TUMOR; NEUTROPENIA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY INSUFFICIENCY; PARAGANGLIOMA; PHEOCHROMOCYTOMA; RADIOIODINATION; REVIEW; SCINTIGRAPHY; THROMBOCYTOPENIA; VOMITING;

EID: 49049091151     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2008.06.002     Document Type: Review

References (75)

1. Kudva Y.C., Sawka A.M., and Young Jr. W.F. Clinical review 164: the laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 88 (2003) 4533-4539
2. McNeil A.R., Blok B.H., Koelmeyer T.D., Burke M.P., and Hilton J.M. Phaeochromocytomas discovered during coronial autopsies in Sydney, Melbourne and Auckland. Aust N Z J Med 30 (2000) 648-652
3. Andersen G.S., Toftdahl D.B., Lund J.O., Strandgaard S., and Nielsen P.E. The incidence rate of phaeochromocytoma and Conn's syndrome in Denmark, 1977-1981. J Hum Hypertens 2 (1988) 187-189
4. Stenstrom G., and Svardsudd K. Pheochromocytoma in Sweden 1958-1981. An analysis of the National Cancer Registry Data. Acta Med Scand 220 (1986) 225-232
5. Beard C.M., Sheps S.G., Kurland L.T., Carney J.A., and Lie J.T. Occurrence of pheochromocytoma in Rochester, Minnesota, 1950 through 1979. Mayo Clin Proc 58 (1983) 802-804
6. Bravo E.L., and Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev 24 (2003) 539-553
7. Goldstein R.E., O'Neill Jr. J.A., Holcomb III G.W., Morgan III W.M., Neblett III W.W., Oates J.A., et al. Clinical experience over 48 years with pheochromocytoma. Ann Surg 229 (1999) 755-764 [discussion 64-6]
8. Amar L., Bertherat J., Baudin E., Ajzenberg C., Bressac-de Paillerets B., Chabre O., et al. Genetic testing in pheochromocytoma or functional paraganglioma. J Clin Oncol 23 (2005) 8812-8818
9. Brouwers F.M., Eisenhofer G., Tao J.J., Kant J.A., Adams K.T., Linehan W.M., et al. High frequency of SDHB germline mutations in patients with malignant catecholamine-producing paragangliomas: implications for genetic testing. J Clin Endocrinol Metab 91 (2006) 4505-4509
10. Brouwers F.M., Elkahloun A.G., Munson P.J., Eisenhofer G., Barb J., Linehan W.M., et al. Gene expression profiling of benign and malignant pheochromocytoma. Ann N Y Acad Sci 1073 (2006) 541-556
11. Benn D.E., Gimenez-Roqueplo A.P., Reilly J.R., Bertherat J., Burgess J., Byth K., et al. Clinical presentation and penetrance of pheochromocytoma/paraganglioma syndromes. J Clin Endocrinol Metab 91 (2006) 827-836
12. Neumann H.P., Pawlu C., Peczkowska M., Bausch B., McWhinney S.R., Muresan M., et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 292 (2004) 943-951
13. Gimenez-Roqueplo A.P., Favier J., Rustin P., Rieubland C., Crespin M., Nau V., et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer Res 63 (2003) 5615-5621
14. Ahlman H. Malignant pheochromocytoma: state of the field with future projections. Ann N Y Acad Sci 1073 (2006) 449-464
15. 131I-MIBG): a comprehensive review of 116 reported patients. J Endocrinol Invest 20 (1997) 648-658
16. Bravo E.L. Evolving concepts in the pathophysiology, diagnosis, and treatment of pheochromocytoma. Endocr Rev 15 (1994) 356-368
17. Ilias I., and Pacak K. Diagnosis and management of tumors of the adrenal medulla. Horm Metab Res 37 (2005) 717-721
18. Amar L., Servais A., Gimenez-Roqueplo A.P., Zinzindohoue F., Chatellier G., and Plouin P.F. Year of diagnosis, features at presentation, and risk of recurrence in patients with pheochromocytoma or secreting paraganglioma. J Clin Endocrinol Metab 90 (2005) 2110-2116
19. Lenders J.W., Eisenhofer G., Mannelli M., and Pacak K. Phaeochromocytoma. Lancet 366 (2005) 665-675
20. Lenders J.W., Pacak K., Walther M.M., Linehan W.M., Mannelli M., Friberg P., et al. Biochemical diagnosis of pheochromocytoma: which test is best?. JAMA 287 (2002) 1427-1434
21. van der Harst E., de Herder W.W., de Krijger R.R., Bruining H.A., Bonjer H.J., Lamberts S.W., et al. The value of plasma markers for the clinical behaviour of phaeochromocytomas. Eur J Endocrinol 147 (2002) 85-94
22. Baudin E., Bidart J.M., Bachelot A., Ducreux M., Elias D., Ruffie P., et al. Impact of chromogranin A measurement in the work-up of neuroendocrine tumors. Ann Oncol 12 Suppl 2 (2001) S79-S82
23. Rao F., Keiser H.R., and O'Connor D.T. Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment. Hypertension 36 (2000) 1045-1052
24. Plouin P.F., and Gimenez-Roqueplo A.P. Pheochromocytomas and secreting paragangliomas. Orphanet J Rare Dis 1 (2006) 49
25. Favier J., Plouin P.F., Corvol P., and Gasc J.M. Angiogenesis and vascular architecture in pheochromocytomas: distinctive traits in malignant tumors. Am J Pathol 161 (2002) 1235-1246
26. Middeke M., Hoffmann S., Hassan I., Wunderlich A., Hofbauer L.C., and Zielke A. In vitro and in vivo angiogenesis in PC12 pheochromocytoma cells is mediated by vascular endothelial growth factor. Exp Clin Endocrinol Diabetes 110 (2002) 386-392
27. Zielke A., Middeke M., Hoffmann S., Colombo-Benkmann M., Barth P., Hassan I., et al. VEGF-mediated angiogenesis of human pheochromocytomas is associated to malignancy and inhibited by anti-VEGF antibodies in experimental tumors. Surgery 132 (2002) 1056-1063 [discussion 63]
28. de Krijger R.R., van der Harst E., van der Ham F., Stijnen T., Dinjens W.N., Koper J.W., et al. Prognostic value of p53, bcl-2, and c-erbB-2 protein expression in phaeochromocytomas. J Pathol 188 (1999) 51-55
29. Khorram-Manesh A., Ahlman H., Jansson S., and Nilsson O. N-cadherin expression in adrenal tumors: upregulation in malignant pheochromocytoma and downregulation in adrenocortical carcinoma. Endocr Pathol 13 (2002) 99-110
30. Salmenkivi K., Haglund C., Arola J., and Heikkila P. Increased expression of tenascin in pheochromocytomas correlates with malignancy. Am J Surg Pathol 25 (2001) 1419-1423
31. Salmenkivi K., Haglund C., Ristimaki A., Arola J., and Heikkila P. Increased expression of cyclooxygenase-2 in malignant pheochromocytomas. J Clin Endocrinol Metab 86 (2001) 5615-5619
32. Koch C.A., Vortmeyer A.O., Diallo R., Poremba C., Giordano T.J., Sanders D., et al. Survivin: a novel neuroendocrine marker for pheochromocytoma. Eur J Endocrinol 146 (2002) 381-388
33. Willenberg H.S., Schott M., Saeger W., Tries A., Scherbaum W.A., and Bornstein S.R. Expression of connexins in chromaffin cells of normal human adrenals and in benign and malignant pheochromocytomas. Ann N Y Acad Sci 1073 (2006) 578-583
34. Gimm O., Krause U., Brauckhoff M., Hoang-Vu C., and Dralle H. Distinct expression of galectin-3 in pheochromocytomas. Ann N Y Acad Sci 1073 (2006) 571-577
35. Hofland J., van Nederveen F.H., Timmerman M.A., Korpershoek E., de Herder W.W., Lenders J.W., et al. Expression of activin and inhibin subunits, receptors and binding proteins in human pheochromocytomas: a study based on mRNA analysis and immunohistochemistry. Clin Endocrinol (Oxf) 66 (2007) 335-340
36. Ilias I., and Pacak K. Anatomical and functional imaging of metastatic pheochromocytoma. Ann N Y Acad Sci 1018 (2004) 495-504
37. Sahdev A., and Reznek R.H. Imaging evaluation of the non-functioning indeterminate adrenal mass. Trends Endocrinol Metab 15 (2004) 271-276
38. Blake M.A., Kalra M.K., Maher M.M., Sahani D.V., Sweeney A.T., Mueller P.R., et al. Pheochromocytoma: an imaging chameleon. Radiographics 24 Suppl 1 (2004) S87-S99
39. Shulkin B.L., Ilias I., Sisson J.C., and Pacak K. Current trends in functional imaging of pheochromocytomas and paragangliomas. Ann N Y Acad Sci 1073 (2006) 374-382
40. Shapiro B., Gross M.D., and Shulkin B. Radioisotope diagnosis and therapy of malignant pheochromocytoma. Trends Endocrinol Metab 12 (2001) 469-475
41. Guller U., Turek J., Eubanks S., Delong E.R., Oertli D., and Feldman J.M. Detecting pheochromocytoma: defining the most sensitive test. Ann Surg 243 (2006) 102-107
42. Reubi J.C., Waser B., Khosla S., Kvols L., Goellner J.R., Krenning E., et al. In vitro and in vivo detection of somatostatin receptors in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab 74 (1992) 1082-1089
43. Kubota A., Yamada Y., Kagimoto S., Shimatsu A., Imamura M., Tsuda K., et al. Identification of somatostatin receptor subtypes and an implication for the efficacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J Clin Invest 93 (1994) 1321-1325
44. Kimura N., Pilichowska M., Date F., Kimura I., and Schindler M. Immunohistochemical expression of somatostatin type 2A receptor in neuroendocrine tumors. Clin Cancer Res 5 (1999) 3483-3487
45. Epelbaum J., Bertherat J., Prevost G., Kordon C., Meyerhof W., Wulfsen I., et al. Molecular and pharmacological characterization of somatostatin receptor subtypes in adrenal, extraadrenal, and malignant pheochromocytomas. J Clin Endocrinol Metab 80 (1995) 1837-1844
46. Kaltsas G., Korbonits M., Heintz E., Mukherjee J.J., Jenkins P.J., Chew S.L., et al. Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 86 (2001) 895-902
47. van der Harst E., de Herder W.W., Bruining H.A., Bonjer H.J., de Krijger R.R., Lamberts S.W., et al. [(123)I]Metaiodobenzylguanidine and [(111)In]octreotide uptake in benign and malignant pheochromocytomas. J Clin Endocrinol Metab 86 (2001) 685-693
48. Bustillo A., Telischi F., Weed D., Civantos F., Angeli S., Serafini A., et al. Octreotide scintigraphy in the head and neck. Laryngoscope 114 (2004) 434-440
49. 111Indium pentetreotide scan detection of familial paragangliomas. Laryngoscope 108 (1998) 228-231
50. Kwekkeboom D.J., van Urk H., Pauw B.K., Lamberts S.W., Kooij P.P., Hoogma R.P., et al. Octreotide scintigraphy for the detection of paragangliomas. J Nucl Med 34 (1993) 873-878
51. Kopf D., Bockisch A., Steinert H., Hahn K., Beyer J., Neumann H.P., et al. Octreotide scintigraphy and catecholamine response to an octreotide challenge in malignant phaeochromocytoma. Clin Endocrinol (Oxf) 46 (1997) 39-44
52. 18F DOPA whole body PET - initial results. Radiology 222 (2002) 507-512
53. 18F-DOPA positron emission tomography for the detection of glomus tumours. Eur J Nucl Med Mol Imaging 30 (2003) 689-694
54. 131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma. J Clin Endocrinol Metab 88 (2003) 4083-4087
55. 18F]fluorodopamine positron emission tomographic (PET) scanning for diagnostic localization of pheochromocytoma. Hypertension 38 (2001) 6-8
56. 18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy. Eur J Nucl Med Mol Imaging 33 (2006) 1115-1122
57. Kayani I., Bomanji J.B., Groves A., Conway G., Gacinovic S., Win T., et al. Functional imaging of neuroendocrine tumors with combined PET/CT using (68)Ga-DOTATATE (DOTA-DPhe(1),Tyr(3)-octreotate) and (18)F-FDG. Cancer (2008)
58. Chrisoulidou A., Kaltsas G., Ilias I., and Grossman A.B. The diagnosis and management of malignant phaeochromocytoma and paraganglioma. Endocr Relat Cancer 14 (2007) 569-585
59. Scholz T., Eisenhofer G., Pacak K., Dralle H., and Lehnert H. Clinical review: current treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 92 (2007) 1217-1225
60. Keiser H.R., Goldstein D.S., Wade J.L., Douglas F.L., and Averbuch S.D. Treatment of malignant pheochromocytoma with combination chemotherapy. Hypertension 7 (1985) I18-I24
61. 131I]iodobenzylguanidine. J Nucl Med 21 (1980) 349-353
62. Vetter H., Fischer M., Muller-Rensing R., Vetter W., and Winterberg B. 131-I-meta-iodobenzylguanidine in treatment of malignant phaeochromocytomas. Lancet 2 (1983) 107
63. Sisson J.C., Shapiro B., Beierwaltes W.H., Glowniak J.V., Nakajo M., Mangner T.J., et al. Radiopharmaceutical treatment of malignant pheochromocytoma. J Nucl Med 25 (1984) 197-206
64. 131I]metaiodobenzylguanidine: results from ten years of experience. J Nucl Biol Med 35 (1991) 269-276
65. 131I]metaiodobenzylguanidine therapy in 20 patients with malignant pheochromocytoma. J Nucl Biol Med 35 (1991) 288-291
66. 131I]metaiodobenzylguanidine: a French multicenter study. J Nucl Biol Med 35 (1991) 284-287
67. 131I]iodobenzylguanidine in the treatment of malignant pheochromocytoma. J Clin Endocrinol Metab 72 (1991) 455-461
68. 131I]metaiodobenzylguanidine treatment in metastatic malignant phaeochromocytoma. J Nucl Biol Med 35 (1991) 277-279
69. 131I]metaiodobenzylguanidine treatment of malignant pheochromocytoma: experience of the Rome group. J Nucl Biol Med 35 (1991) 295-299
70. Colombo L., Lomuscio G., Vignati A., and Dottorini M.E. Preliminary results of [131]metaiodobenzylguanidine treatment in metastatic malignant pheochromocytoma. J Nucl Biol Med 35 (1991) 300-304
71. 131I MIBG: a long survival. An Med Interna 20 (2003) 575-578
72. 131I-MIBG). Ann N Y Acad Sci 1073 (2006) 465-490
73. Gedik G.K., Hoefnagel C.A., Bais E., and Valdes Olmos R.A. (131)I-MIBG therapy in metastatic phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging (2007)
74. 131I-metaiodobenzylguanidine therapy for 12 patients with malignant pheochromocytoma. Cancer 98 (2003) 239-248
75. Safford S.D., Coleman R.E., Gockerman J.P., Moore J., Feldman J.M., Leight Jr. G.S., et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 134 (2003) 956-962 [discussion 62-3]